Evidence map›Paper›PMID 40197709›Full record

Trial reportThe clinical respiratory journal2025

Ruxolitinib for Emergency Treatment of COVID-19-Associated Cytokine Storm: Findings From an Expanded Access Study.

Jeffrey Weinstein, Nikhil Jagan, Shawnta Lorthridge-Jackson, J E Hamer-Maansson, Peg Squier

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04355793 (An Open-Label Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04355793 no longer availablenot on this map

An Open-Label Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

Typeexpanded_accessSponsorIncyte CorporationConditionsCOVID-19ArmsRuxolitinib
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mucosal implications of oral Jak3-targeted drugs in COVID patients.Molecular medicine (Cambridge, Mass.) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jeffrey WeinsteinDepartment of Clinical Quality and Infection Prevention and Control, Kettering Health Network, Dayton, Ohio, USA.ORCID https://orcid.org/0000-0002-3428-2558
Nikhil JaganDepartment of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USA.
Shawnta Lorthridge-JacksonMedical Affairs, Incyte Corporation, Wilmington, Delaware, USA.
J E Hamer-MaanssonMedical Affairs, Incyte Corporation, Wilmington, Delaware, USA.
Peg SquierMedical Affairs, Incyte Corporation, Wilmington, Delaware, USA.

Funding

Incyte Corporation
6 · The paper itself

Abstract

introductionThis expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID-19-associated cytokine storm in patients eligible for hospitalization (NCT04355793).

methodsPatients received ruxolitinib 5 mg twice daily (preferred regimen when tolerated) or once daily for ≤ 14 days, or until determination of no clinical benefit was made. Outcomes were clinical status, physician-assessed clinical benefit, and serious adverse event (SAE) incidence.

resultsOf 312 patients, 45.5% achieved ≥ 1-point clinical status improvement. Physician-assessed clinical benefit was reported in 42.6% of evaluable patients. SAEs occurred in 42.9%, with 2.6% experiencing an SAE suspected to be ruxolitinib related.

conclusionsOverall, some hospitalized patients with COVID-19-associated cytokine storm who received ruxolitinib experienced clinical status improvement; ruxolitinib was well tolerated.

trial registrationClinicalTrials.gov identifier: NCT04355793.

Indexed as

COVID-19 Drug TreatmentCytokine Release SyndromePyrazolesAdultAgedCOVID-19FemaleHumansJanus Kinase InhibitorsMaleMiddle AgedNitrilesPyrimidinesSARS-CoV-2Treatment OutcomeJanus Kinase InhibitorsNitrilesPyrazolesPyrimidinesruxolitinibacute respiratory distress syndromeCOVID‐19cytokine release syndromeexpanded accesshospitalizationJanus kinase inhibitors

Identifiers

PMID40197709
PMCPMC11976455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.